Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin

This publication has 69 references indexed in Scilit:

• Benefits and Risks of HMG-CoA Reductase Inhibitors in the Prevention of Coronary Heart Disease A Reappraisal
  Drug Safety, 1996
• Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase Inhibitor
  Arteriosclerosis, Thrombosis, and Vascular Biology, 1995
• The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
• Branch-point reactions in the biosynthesis of cholesterol, dolichol, ubiquinone and prenylated proteins
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1994
• Effect of a long-term treatment with lovastatin or fenofibrate on hepatic and cardiac ubiquinone levels in cardiomyopathic hamster
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
• Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study
  The Journal of Clinical Pharmacology, 1993
• Hepatic uptake and metabolism of ingested 24-hydroxycholesterol and 24(S),25-epoxycholesterol
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993
• Effects of cholestyramine on lipoprotein levels and metabolism in Syrian hamsters
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1992
• Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase synthesis in Syrian hamster C100 cells by mevinolin, 25-hydroxycholesterol, and mevalonate: The role of posttranscriptional control
  Somatic Cell and Molecular Genetics, 1992
• Regulation of the mevalonate pathway
  Nature, 1990